On May 12th, the biaseparations.com website will be retired and migrated tosartorius.com.Learn moreabout our combined offering today!

3rd Gene Therapy for Muscular Disorders

Towards safer AAV gene therapy

Speaker: Aleš Štrancar, Managing Director, Sartorius BIA Separations

  • Recent clinical trials revealed the immune response to AAV vectors is likely to be a bottleneck in AAV gene therapy.
  • One of the key reasons for the immune response is AAV purity. Improved manufacturing, especially purification process, is therefore mandatory for safer gene therapy.
  • In addition to hc proteins and hc DNA removal of empty and partial AAV capsids, infectious viruses and endotoxin will be presented in this paper.

Register Now!

  • from
    21Feb2023
    until
    23Feb2023
  • 3rd Gene Therapy for Muscular Disorders